Biogen Stock Climbs After Goldman Adds to its 'Conviction Buy' List
The firm has a $338 price target on the company, a potential 17% upside from the stock's previous closing price.

Biogen Inc. (BIIB) shares were up 1.38% to $292.62 in early morning trading Monday after the company was added to Goldman Sachs "conviction buy" list Wednesday. 

The firm has a $338 price target on the company, which represents a potential 17% upside from the stock's previous closing price. 

"On BIIB's base [multiple sclerosis] franchise, we view investor concerns on competition and pricing as overblown," the firm said. "Finally, BIIB has a relatively under-leverage balance sheet, and we expect [free cash flow yield] and US cash to grow."

Watch More with TheStreet:

More from Stocks

Dow Falls, S&P 500 Trades Lower as P&G and Apple Slump

Dow Falls, S&P 500 Trades Lower as P&G and Apple Slump

Will Tesla Stock Tumble 33% to $195?

Will Tesla Stock Tumble 33% to $195?

Tesla Is Crowdsourcing its Newest AI Features

Tesla Is Crowdsourcing its Newest AI Features

AAP Exclusive: Cramer Says The President is No Longer on the Side of the Bulls

AAP Exclusive: Cramer Says The President is No Longer on the Side of the Bulls

Video: Jim Cramer on Apple, Procter & Gamble, Nucor and Acacia Communications

Video: Jim Cramer on Apple, Procter & Gamble, Nucor and Acacia Communications